Difference between revisions of "Part:BBa K4156085"

 
 
(One intermediate revision by the same user not shown)
Line 3: Line 3:
 
<partinfo>BBa_K4156085 short</partinfo>
 
<partinfo>BBa_K4156085 short</partinfo>
  
−
To be refined
+
CDD-IRGD is Bit1 cell death domain  fusion protein with tumour perforator protein.
 +
 
 +
<!-- Add more about the biology of this part here -->
  
−
<!-- Add more about the biology of this part here
 
 
===Usage and Biology===
 
===Usage and Biology===
  
−
<!-- -->
+
CDD-iRGD activates the host immune response and triggers apoptosis of tumour cells. iRGD tumor-penetrating peptide-modified lysing adenovirus shows enhanced tumor transmission, intra-tumor dissemination and anti-tumor efficacy.
 +
 
 +
CDD-iRGD activates host immune response and triggers apoptosis of tumor cells. the protein is expressed with the constitutive promoter plac, thus exerting an anti-tumor effect. Therefore, we plan to use CDD-IRGD as a tumor treatment factor<sup>[1]</sup>.
 +
 
 +
===References===
 +
 
 +
<i>
 +
1 Chen R, Braun GB, Luo X, Sugahara KN, Teesalu T, Ruoslahti E. Application of a proapoptotic peptide to intratumorally spreading cancer therapy. Cancer Res. Feb 15 2013;73(4):1352-61. doi:10.1158/0008-5472.Can-12-1979
 +
 
 +
</i>
 +
 
 
<span class='h3bb'>Sequence and Features</span>
 
<span class='h3bb'>Sequence and Features</span>
 
<partinfo>BBa_K4156085 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4156085 SequenceAndFeatures</partinfo>

Latest revision as of 11:49, 11 October 2022


CDD-iRGD

CDD-IRGD is Bit1 cell death domain fusion protein with tumour perforator protein.


Usage and Biology

CDD-iRGD activates the host immune response and triggers apoptosis of tumour cells. iRGD tumor-penetrating peptide-modified lysing adenovirus shows enhanced tumor transmission, intra-tumor dissemination and anti-tumor efficacy.

CDD-iRGD activates host immune response and triggers apoptosis of tumor cells. the protein is expressed with the constitutive promoter plac, thus exerting an anti-tumor effect. Therefore, we plan to use CDD-IRGD as a tumor treatment factor[1].

References

1 Chen R, Braun GB, Luo X, Sugahara KN, Teesalu T, Ruoslahti E. Application of a proapoptotic peptide to intratumorally spreading cancer therapy. Cancer Res. Feb 15 2013;73(4):1352-61. doi:10.1158/0008-5472.Can-12-1979

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]